An interventional study of Jin-shui Huan-xian granule and Jin-shui Huan-xian granule placebo in Idiopathic Pulmonary Fibrosis(IPF), sponsored by Henan University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Henan University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 11th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 3 with no phase, reaches primary completion later than 13 of the 28 other live ones, and was the 47th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
InSilico Medicine Hong Kong Limited · Sites in China
Ages 40+
AstraZeneca · Sites in China, United States, Argentina and 20 more countries
Ages 40+
Dragonboat Biopharmaceutical Company Limited · Sites in China
Ages 40+
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Sites in China
Ages 40–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 14
First in 2012; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 384 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 83 across the 60 interventional studies, 310 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 67 have an industry lead sponsor. The 10 most frequent:
Henan University of Traditional Chinese Medicine is the lead sponsor of 55 studies on the registry; 31 are open to participants now.
Henan University of Traditional Chinese Medicine has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06267183Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | 2026-11-30 |
| NCT07820254Shanghai Pulmonary Hospital, Shanghai, ChinaInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | 2026-12-31 |
| NCT07121413Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis(IPF)
This study will enroll 384 patients with idiopathic pulmonary fibrosis (IPF) and adopts a randomized, quadruple-masked, placebo-controlled trial design. Participants will be randomly assigned to either an experimental group or a control group. On the basis of guideline-directed standard treatment, the experimental group will receive Jin-shui Huan-xian Formula, while the control group will receive a matching placebo. Participants, care providers, investigators, and outcome assessors will remain blinded to treatment allocation. The treatment duration is 52 weeks. Forced vital capacity (FVC) is the primary outcome measure, while acute exacerbations, other pulmonary function parameters (including DLCO and DLCO%), exercise capacity, and quality of life are secondary outcome measures. Safety assessments include routine blood tests, urinalysis, liver function, renal function, and electrocardiography. The study aims to evaluate the efficacy and safety of Jin-shui Huan-xian Formula in slowing the decline in pulmonary function in patients with IPF and to generate high-quality clinical evidence for its use as an adjunctive treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group was given Jin-shui Huan-xian Formula in addition to the treatment guided by the guideline "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ".
Drug: Jin-shui Huan-xian granule
Participants in the control group will receive Jin-shui Huan-xian granule placebo in addition to guideline-directed treatment based on the "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Drug: Jin-shui Huan-xian granule placebo
Jin-shui Huan-xian Granules: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.
Also known as: Jin-shui Huan-xian Granules
Jin-shui Huan-xian granule placebo: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell.
Forced vital capacity (FVC)
FVC will be used to assess pulmonary function.
Time frame: The change in absolute FVC value before treatment and at 52 weeks of treatment
The time of the first acute exacerbation
The time of the patients' first acute exacerbation will be recorded.
Time frame: Up to week 52.
Frequency of acute exacerbation
Frequency of acute exacerbation will be recorded.
Time frame: Up to week 52
Frequency of acute exacerbations resulting in hospitalization
Frequency of acute exacerbation resulting in hospitalization will be recorded.
Time frame: Up to week 52
Frequency of acute exacerbations resulting in ICU admission
Frequency of acute exacerbation resulting in ICU admission will be recorded.
Time frame: Up to week 52
Annual acute exacerbation rate
The annual acute exacerbation rate will be calculated in each group at the end of the trial.
Time frame: Up to week 52
Annual hospitalization rate due to acute exacerbation
The Annual hospitalization rate due to acute exacerbation will be calculated in each group at the end of the trial.
Time frame: Up to week 52
Annual rate of ICU admission due to acute exacerbation
The Annual ICU admission rate due to acute exacerbation will be calculated in each group at the end of the trial.
Time frame: Up to week 52.
Diffusing Capacity of Carbon Monoxide(DLCO)
DLCO will be used to assess pulmonary function.
Time frame: Change from baseline DLCO at week 13, 26, 39 and 52.
Percent of Diffusing Capacity of Carbon Monoxide(DLCO%)
DLCO% will be used to assess pulmonary function.
Time frame: Change from baseline DLCO% at week 13, 26, 39 and 52.
Percent of Forced Vital Capacity(FVC%)
FVC% will be used to assess pulmonary function.
Time frame: Change from baseline FVC%at week 13, 26, 39 and 52.
Alveolar ventilation(VA)
VA will be used to assess pulmonary function.
Time frame: Change from baseline VA at week 13, 26, 39 and 52.
.Diffusion capacity for carbon monoxide per liter of alveolar volume(DLCO/VA)
DLCO/VA will be used to assess pulmonary function.
Time frame: Change from baseline DLCO/VA at week 13, 26, 39 and 52.
All-cause mortality rate
The all-cause mortality rate will be calculated in each group at the end of the trial.
Time frame: Up to week 52.
Mortality rate due to acute exacerbation
The mortality rate due to acute exacerbation will be calculated in each group at the end of the trial.
Time frame: Up to week 52.
Progression-Free Survival(PFS)
According to "Idiopathic Pulmonary Fibrosis in Adults (Update) and Progressive Pulmonary Fibrosis: An Official Clinical Practice Guideline of the ATS/ERS/JRS/ALAT ": The time from enrollment to the first meeting of disease progression (at least two of respiratory symptoms, physiological evidence and radiological evidence).
Time frame: Up to week 13, 26, 39 and 52.
Six Minute Walk Test (6MWT)
6MWT will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity.
Time frame: Change from baseline 6MWT at week 13, 26, 39 and 52.
Imaging findings
Changes in chest CT imaging will be assessed before and after JSHX treatment to evaluate its impact on pulmonary fibrosis in IPF patients. High-resolution computed tomography (HRCT) will be used to quantify alterations in lung parenchyma, including ground-glass opacities, reticulation, and honeycombing. Quantitative software-based analysis (e.g., histogram-based texture analysis) may be applied to standardize the evaluation. Radiologists blinded to treatment allocation will independently review the images to ensure objectivity.
Time frame: Up to week 26, 52.
A Tool to Assess Quality of life (ATAQ-IPF)
ATAQ - IPF is currently a specialized scale for evaluating the quality of life of patients, consisting of 13 dimensions and 74 items, with each item being scored from 1 to 5 points. A higher score indicates a worse condition.
Time frame: Change from baseline ATAQ-IPF scores at week 13, 26, 39 and 52.
Idiopathic pulmonary fibrosis patient reported outcomes (IPF-PRO)
IPF-PRO is a scale used to evaluate the quality of life of patients, where patients recall their condition over the past two weeks based on their subjective experience. The evaluation covers four domains: Physiological, Psychological, Environmental, and Satisfaction, comprising 18 items in total. Higher scores indicate worse conditions.
Time frame: Change from baseline SGRQ scores at week 13, 26, 39 and 52.
Dyspnea
Dyspnea will be assessed by 22.modified Medical Research Council(mMRC) scores. A score of 0-4 will be given according to the degree of immediate dyspnea. A higher score indicates a worse condition.
Time frame: Change from baseline CAT scores at week 13, 26, 39 and 52.
Cough Visual analog scale(VAS)
The Cough VAS is a method of quantitatively assessing cough symptoms using the Visual Analogue Scale. The score ranges from 1 to 100, a higher score indicates a worse condition.
Time frame: Change from baseline CAT scores at week 13, 26, 39 and 52.
Clinical symptoms and Signs
Clinical symptoms and Signs will be evaluated through a scale. The scale includes coughing, expectoration, chest tightness, shortness of breath, wheezin. The Clinical Symptom Rating Scale includes 6 items: cough, expectoration, chest tightness, shortness of breath, wheezing, and cyanosis. Each item has a score of 0-3, totaling 18 points. The higher the score, the worse he patient's condition.
Time frame: Change from baseline clinical symptoms and signs up at week 13, 26, 39 and 52.
Krebs Von den Lungen-6 (KL-6)
Detect the level of KL-6.
Time frame: Change from baseline KL-6 level at week 13, 26, 39 and 52.
Interleukin-6 (IL-6)
Detect the level of IL-6.
Time frame: Change from baseline IL-6 level at week 13, 26, 39 and 52.
Ferritin
Detect the level of Ferritin.
Time frame: Change from baseline Ferritin level at week 13, 26, 39 and 52.
Immunoglobulin
Detect the level of immunoglobulins
Time frame: Change from baseline immunoglobulins level at week 13, 26, 39 and 52.
T, B and NK lymphocyte subsets
Detect the level of T, B and NK lymphocyte subsets. The common indicators of TBNK lymphocyte subsets and their respective units of measurement are as follows: the total T cells (CD3+), measured in cells per microliter (cells/µL); the helper T cells (CD3+CD4+), measured in cells/µL; the cytotoxic T cells (CD3+CD8+), measured in cells/µL; the B cells (CD19+), measured in cells/µL; the natural killer cells (NK cells, CD16+CD56+, CD3-), measured in cells/µL; and the CD4/CD8 ratio, which is a unitless ratio. These indicators are detected by flow cytometry and can reflect the immune function status of the body.
Time frame: Change from baseline T, B and NK lymphocyte subsets level at week 13, 26, 39 and 52.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.
Of 49 non-industry interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 27 months is close to that.
Counting every sponsor, half of 52 studies reached it within 26 months; a quarter within 12 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Aug 2025 → Sep 2025 and primary completion Jun 2028 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →
Henan University of Traditional Chinese Medicine